Andromeda Biotech is a biopharmaceutical company focused on the development of innovative therapies for autoimmune
diabetes.
Currently in phase III clinical trials, DiaPep277, the Company's lead product presents a novel therapeutic approach for type
1 diabetes (T1D).
DiaPep277 is a unique peptide that prevents the destruction of insulin producing cells in the pancreas. By modulating the
immune system, DiaPep277 preserves the natural function of pancreatic cells.